Clinical Trial Update: Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and early efficacy of ANX-042 in humans with cardiorenal syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiorenal Syndrome
• Heart Failure

Drugs mentioned

• ANX-042

Snippet

Sponsor: Mayo Clinic | Conditions: Heart Failure, Cardiorenal Disease | Phase 1 | Status: COMPLETED